Is CLBT a good stock to buy right now?

Based on our 6-factor quantitative model, Cellebrite DI Ltd. (CLBT) receives a "Reduce" rating with a composite score of 43.7/100. It is ranked #2,275 out of 4,446 stocks. Key factor scores: Quality 49/100, Value 38/100, Momentum 37/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for CLBT?

Cellebrite DI Ltd. (CLBT) has a "Reduce" rating and 2-star score. The composite score of 43.7 ranks it #2,275 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is CLBT in?

Cellebrite DI Ltd. operates in the Technology sector (Computer Software industry) with a market cap of $3.46 billion. It is classified as a mid-cap stock.

Does CLBT pay a dividend?

CLBT does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is CLBT's P/E ratio?

P/E ratio data is not currently available for CLBT, which may indicate the company is not yet profitable.

How profitable is CLBT?

CLBT's quality factor score is 49/100. Gross margin: 84.4%. ROE: -336.9% vs sector average -1.4%. High margins suggest pricing power and competitive moats.

How is CLBT valued compared to peers?

CLBT's value factor score is 38/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is CLBT's debt level?

CLBT's debt-to-equity ratio is 0%. Sector average: 43%. Low leverage suggests conservative financial management.

CLBT has a beta of 0.78, meaning it is less volatile than the market. Stability score: 55/100.

Does CLBT have high short interest?

CLBT's short interest factor score is 64/100 (higher = less short selling). Moderate short interest.

CLBT Stock Analysis: Top Mid-Cap Reduce (Score 43.7/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
CLBT	-7.59%	-10.59%	-18.89%	-31.17%	-34.62%	-	-	-
Industry Proxy XLK	+0.27%	+5.31%	+3.48%	-1.32%	-30.31%	-	-	-
U.S. Market SPY	+0.58%	+3.77%	+1.12%	-0.29%	+23.93%	-	-	-
Alpha vs Market	-8.17%	-14.36%	-20.01%	-30.88%	-58.55%	-	-	-
Alpha vs Sector	-7.86%	-15.90%	-22.37%	-29.85%	-4.31%	-	-	-

Metric	CLBT	Benchmark
P/E Ratio	-3.1x	-107%
EV/EBITDA	—	—
Price / Book	10.5x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
VRSN VERISIGN INC/CA	56	79	59	40	30.7x	-41.1%	88.0%	50.6%	8.3%	-87.0x	$23.0B	VS
IHS IHS Holding Ltd	55	42	63	63	-	-616.0%	48.0%	-96.1%	-	365.0x	$2.8B	VS
LHX L3HARRIS TECHNOLOGIES, INC. /DE/	55	50	52	66	37.5x	9.0%	25.5%	8.1%	10.3%	110.0x	$66.1B	VS
ESP ESPEY MFG & ELECTRONICS CORP	53	48	44	71	25.8x	12.8%	29.0%	17.1%	-11.7%	66.0x	$169M	VS
NYAX Nayax Ltd.	52	38	46	78	-	-13.6%	44.6%	-1.8%	-	30.0x	$2.2B	VS
ESE ESCO TECHNOLOGIES INC	52	49	40	69	65.6x	7.4%	40.8%	10.4%	16.3%	9.0x	$7.6B	VS
INTT INTEST CORP	52	50	32	72	-	-3.2%	43.1%	-3.1%	-22.8%	46.0x	$179M	VS
KARO Karooooo Ltd.	49	50	72	53	-	117.1%	69.5%	20.3%	-	10.0x	$1.6B	VS
MTC MMTec, Inc.	47	32	40	96	-	-1,370.8%	81.6%	-4,879.7%	-	120.0x	$136M	VS
CCLD CareCloud, Inc.	47	38	71	60	12.4x	18.5%	48.0%	9.6%	10.6%	47.0x	$154M	VS
CLBT Cellebrite DI Ltd.	44	49	38	37	-	-336.9%	84.4%	-70.5%	-	0.0x	$3.5B

Key Ratio	TTM	2024	2023	2022	2021	2020
Gross Margin %	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%
Operating Margin %	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%
EBITDA Margin %	-0.7%	-0.7%	-0.2%	0.5%	0.4%	0.1%
Net Margin %	-0.7%	-0.7%	-0.2%	0.4%	0.3%	0.0%
FCF Margin %	30.8%	30.8%	29.8%	35.8%	12.6%	31.0%
ROE %	-3.4%	-0.8%	-2.4%	1.6%	-97.3%	0.1%
ROA %	-1.6%	-0.4%	-0.2%	0.3%	0.2%	0.0%
ROIC %	31.1%	31.1%	-	-	-	-

Line Item	TTM	2024	2023	2022	2021	2020
	$401M	$401M	$325M	$271M	$246M	$195M
	$339M	$339M	$272M	$220M	$204M	$157M
Gross Margin	84.4%	84.4%	83.6%	81.3%	82.7%	80.6%
	—	$98M	$84M	$81M	$66M	$54M
Depreciation	—	$8M	$9M	$9M	$7M	$6M
	$57M	$57M	$33M	$1M	$14M	$9M
EBIT	$57M	$57M	$33M	$1M	$14M	$9M
EBITDA	-$268M	-$268M	-$67M	$130M	$89M	$17M
Operating Margin	14.2%	14.2%	10.2%	0.4%	5.6%	4.7%
EBITDA Margin	-66.9%	-66.9%	-20.5%	47.9%	36.3%	8.9%
	—	$7M	$6M	-$45K	$11M	$6M
	-$283M	-$283M	-$81M	$121M	$71M	$6M
Net Margin	-70.5%	-70.5%	-24.9%	44.6%	29.0%	3.0%
	$-1.35	$-1.35	$-0.43	$0.64	$0.49	$-0.08
Diluted EPS	$-1.35	$-1.35	$-0.43	$0.64	$0.49	$-0.08

Cellebrite DI Ltd. (CLBT) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Cellebrite DI Ltd. Do?

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation. Cellebrite DI Ltd. (CLBT) is classified as a mid-cap stock in the Technology sector, specifically within the Computer Software industry. The company is led by CEO Yossi Carmil and employs approximately 900 people. With a market capitalization of $3.5B, CLBT is one of the notable companies in the Technology sector.

Cellebrite DI Ltd. (CLBT) Stock Rating — Reduce (April 2026)

As of April 2026, Cellebrite DI Ltd. receives a Reduce rating with a composite score of 43.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CLBT ranks #2,275 out of 4,446 stocks in our coverage universe. Within the Technology sector, Cellebrite DI Ltd. ranks #246 of 584 stocks, placing it in the upper half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLBT Stock Price and 52-Week Range

Cellebrite DI Ltd. (CLBT) currently trades at $12.35. The stock lost $0.06 (0.5%) in the most recent trading session. The 52-week high for CLBT is $20.86, which means the stock is currently trading -40.8% from its annual peak. The 52-week low is $11.76, putting the stock 5.0% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is CLBT Overvalued or Undervalued? — Valuation Analysis

Cellebrite DI Ltd. (CLBT) carries a value factor score of 38/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 10.50x, versus the sector average of 3.16x. The price-to-sales ratio is 2.20x, compared to 1.06x for the average Technology stock.

At current multiples, Cellebrite DI Ltd. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cellebrite DI Ltd. Profitability — ROE, Margins, and Quality Score

Cellebrite DI Ltd. (CLBT) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -336.9%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -163.9% versus the sector average of -1.0%.

On a margin basis, Cellebrite DI Ltd. reports gross margins of 84.4%, compared to 50.9% for the sector. The operating margin is 14.2% (sector: -0.5%). Net profit margin stands at -70.5%, versus -1.5% for the average Technology stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CLBT Debt, Balance Sheet, and Financial Health

Cellebrite DI Ltd. has a debt-to-equity ratio of 0.0%, compared to the Technology sector average of 43.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $192M.

CLBT has a beta of 0.78, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Cellebrite DI Ltd. is 55/100, reflecting average volatility within the normal range for its sector.

Cellebrite DI Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cellebrite DI Ltd. reported revenue of $401M and earnings per share (EPS) of $-1.35. Net income for the quarter was $-283M. Gross margin was 84.4%. Operating income came in at $57M.

In FY 2024, Cellebrite DI Ltd. reported revenue of $401M and earnings per share (EPS) of $-1.35. Net income for the quarter was $-283M. Gross margin was 84.4%. Revenue grew 23.4% year-over-year compared to FY 2023. Operating income came in at $57M.

In FY 2023, Cellebrite DI Ltd. reported revenue of $325M and earnings per share (EPS) of $-0.43. Net income for the quarter was $-81M. Gross margin was 83.6%. Revenue grew 20.1% year-over-year compared to FY 2022. Operating income came in at $33M.

In FY 2022, Cellebrite DI Ltd. reported revenue of $271M and earnings per share (EPS) of $0.64. Net income for the quarter was $121M. Gross margin was 81.3%. Revenue grew 9.9% year-over-year compared to FY 2021. Operating income came in at $1M.

Over the past 6 quarters, Cellebrite DI Ltd. has demonstrated a growth trajectory, with revenue expanding from $195M to $401M. Investors analyzing CLBT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLBT Dividend Yield and Income Analysis

Cellebrite DI Ltd. (CLBT) does not currently pay a dividend. This is common among smaller companies in the Computer Software industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

CLBT Momentum and Technical Analysis Profile

Cellebrite DI Ltd. (CLBT) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

CLBT vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, Cellebrite DI Ltd. (CLBT) ranks #246 out of 584 stocks based on the Blank Capital composite score. This places CLBT in the upper half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing CLBT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLBT vs S&P 500 (SPY) comparison to assess how Cellebrite DI Ltd. stacks up against the broader market across all factor dimensions.

CLBT Next Earnings Date

No upcoming earnings date has been announced for Cellebrite DI Ltd. (CLBT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLBT? — Investment Thesis Summary

The quantitative profile for Cellebrite DI Ltd. suggests caution. The value score of 38/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance.

In summary, Cellebrite DI Ltd. (CLBT) earns a Reduce rating with a composite score of 43.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLBT stock.

Related Resources for CLBT Investors

Explore more research and tools: CLBT vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLBT head-to-head with peers: CLBT vs IHS, CLBT vs VRSN, CLBT vs ESE.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Cellebrite Spring Release: New Industry-Leading Device Access and Multi-Cloud Expansion

Cellebrite (CLBT) Completes Acquisition of Drone Forensics Leader SCG Canada to Enhance AI Platform

Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat

What Cellebrite DI (CLBT)'s Cloud-Based Corellium Integration Means For Shareholders

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Technology Stocks